| Previous Close | 5.50 |
| Open | 5.50 |
| Bid | N/A |
| Ask | N/A |
| Strike | N/A |
| Expire Date | N/A |
| Day's Range | 5.50 - 5.50 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
ZacksReasons to Retain PacBio Stock in Your Portfolio for Now
PACB's strong product demand and continued focus on R&D raise optimism about the stock.
ZacksPacBio Shares Rise After NCCS Partnership for Cancer Genomics Research
PACB partners with NCCS to enhance cancer research using the Onso short-read platform and Revio long-read sequencing, advancing precision oncology in Singapore and Asia.
GlobeNewswirePacBio Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing
Groundbreaking collaboration to unlock the full potential of PacBio’s Onso technology, accelerating breakthroughs in cancer genomics across AsiaSINGAPORE, Oct. 11, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the signing of a new Research Collaboration Agreement (RCA) with the National Cancer Centre of Singapore (NCCS). This collaboration aims to accelerate cancer research by leveraging PacBio's advance
